Skip to main content
  • Thrombogenics

    Thrombogenics will pay €1 million to Galapagos to further explore integrin antagonists as treatment for diabetic retinopathy. The license agreement will give ThromboGenics access to a collection of integrin antagonists developed by Galapagos.

    “We are pleased to have signed this in-licensing deal with Galapagos which will provide us with access to a collection of integrin antagonists, an exciting class of drugs being developed for back of the eye disease. This deal is a further important step in our goal to build one of the industry’s leading pipelines targeting diabetic eye disease based on novel disease modifying compounds,“ said Patrik De Haes, MD, CEO of ThromboGenics.

    Belgian-based Galapagos has similar strategic alliances with GlaxoSmithKline, MorphoSys, Servier and AbbVie to develop small molecules for the treatment of a variety of inflammatory and oncology diseases.